VTX958 225 mg BID and 300 mg BID doses achieved statistical significance on the primary endpoint (PASI 75) and all key secondary endpoints at Week 16
Efficacy results did not meet the internal target to support further development of VTX958 in psoriasis; Ventyx to terminate Phase 2 trials of VTX958 in plaque psoriasis and psoriatic arthritis
The ongoing Phase 2 trial of VTX958 in Crohn’s disease will continue to enroll; Ventyx intends to conduct an interim efficacy analysis in Q1 2024
Cash, cash equivalents and marketable securities of $300.8M as of September 30, 2023
Ventyx to host conference call and webcast today at 4:30 PM ET
Ventyx will host a conference call today at 4:30 p.m. ET to discuss the results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis. To participate in the conference call, please dial (800) 225-9448 (U.S.) or (203) 518-9708 (international) and reference passcode VTYX1106. A live webcast will be available in the Investors section of the company’s website at www.ventyxbio.com. A recording of the webcast will be available for thirty days following the call.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.